PD-L1 expression in HNPCC-associated colorectal cancer

Shiraliyeva, Naila; Friedrichs, Jacqueline; Buettner, Reinhard; Friedrichs, Nicolaus

doi:10.1016/j.prp.2017.09.012

Cited by 6 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Expressions of PD-L1 in cancer patients are associated with depth of invasion, lymphatic metastasis, pathological pattern and overall survival. PD-L1 monoclonal antibody in melanoma and non-small cell lung cancer and other tumours have a good curative effect but poor curative effect on the digestive system tumours [21][22][23]. Recently, PD-L1 has been reported to be expressed in TAFs [24].…”

Section: Introductionmentioning

confidence: 99%

Relationship between the expressions of PD-L1 and tumour-associated fibroblasts in gastric cancer

et al. 2019

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

Previous studies have focused on the changes of tumour cells in immune escape, and less is known about the effect of tumour microenvironment (TME) on immune escape. Tumour-associated fibroblasts (TAF) is an important part of the TME and has special physiological and biochemical characteristics, but the specific mechanism has not been clarified. In order to investigate the effect of TAF on the expression of PD-L1 in gastric cancer cells, gastric cancer cell lines MNK45, SGC7901 were non-contact coculturing with TAF 1, 3 and 7 d via transwell. PD-L1 mRNA and protein expression were detected using qRT-PCR and FCM. Then, 95 cases of gastric cancer tissues were selected and evaluated PD-L1 and TAF expressions by immunohistochemical examination. The results showed that the mRNA and protein expression of PD-L1 in the experiment group were significantly higher than that in the control group. PD-L1 expression was associated with massive lymphocyte infiltration, diffuse/mixed histology and intratumoral TAFs in gastric cancers. In conclusion, TAFs promoted the growth in gastric cancer cell lines by increased the PD-L1 expression. ARTICLE HISTORY

show abstract

Section: Introductionmentioning

confidence: 99%

Relationship between the expressions of PD-L1 and tumour-associated fibroblasts in gastric cancer

et al. 2019

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

show abstract

“…In LS-CRC, PD-L1 expression is more frequently observed on immune cells at the invasive margin; peri- and intratumoral macrophages also show extensive PD-L1 expression, while expression is rarely observed on tumor cells themselves [ 76 ]. LS tumors have lower PD-L1 expression than their sporadic MSI-H CRC counterparts, with expression predominantly demonstrated in a focal pattern and widely varied regarding whether expressed in both tumor cells and stromal macrophages or in only one type of cell versus the other [ 84 , 85 ]. PD-L1 expression in TILs, but not tumor cells, has been shown to predict prognosis.…”

Section: Immune Evasion In Lynch Syndromementioning

confidence: 99%

“…Similarly, a significant association between high PD-L1 levels and high levels of CD3 + and CD8 + cells in LS has been recognized [ 76 ]. In this regard, germline mutational status (e.g., MLH1-/PMS2- vs MSH2-/MSH6-) may occupy a less critical role with respect to PD-L1 expression [ 84 ].…”

Section: Immune Evasion In Lynch Syndromementioning

confidence: 99%

Immunology of Lynch Syndrome

Pastor

Schlom

2021

Curr Oncol Rep

View full text Add to dashboard Cite

Purpose of Review Patients with Lynch syndrome have a high probability of developing colorectal and other carcinomas. This review provides a comprehensive assessment of the immunologic aspects of Lynch syndrome pathogenesis and provides an overview of potential immune interventions for patients with Lynch syndrome polyps and Lynch syndrome–associated carcinomas. Recent Findings Immunogenic properties of the majority of Lynch syndrome polyps and associated cancers include microsatellite instability leading to a high mutational burden and the development of novel frameshift peptides, i.e., neoantigens. In addition, patients with Lynch syndrome develop T cell responses in the periphery and in the tumor microenvironment (TME) to tumor-associated antigens, and a proinflammatory cytokine TME has also been identified. However, Lynch syndrome lesions also possess immunosuppressive entities such as alterations in MHC class I antigen presentation, TGFβ receptor mutations, regulatory T cells, and upregulation of PD-L1 on tumor-associated lymphocytes. Summary The rich immune microenvironment of Lynch syndrome polyps and associated carcinomas provides an opportunity to employ the spectrum of immune-mediating agents now available to induce and enhance host immune responses and/or to also reduce immunosuppressive entities. These agents can be employed in the so-called prevention trials for the treatment of patients with Lynch syndrome polyps and for trials in patients with Lynch syndrome–associated cancers.

show abstract

Overexpression of FAM3C is associated with poor prognosis in oral squamous cell carcinoma

Xiao

et al. 2019

Pathology - Research and Practice

View full text Add to dashboard Cite

PD-L1 expression in HNPCC-associated colorectal cancer

Cited by 6 publications

References 19 publications

Relationship between the expressions of PD-L1 and tumour-associated fibroblasts in gastric cancer

Relationship between the expressions of PD-L1 and tumour-associated fibroblasts in gastric cancer

Immunology of Lynch Syndrome

Overexpression of FAM3C is associated with poor prognosis in oral squamous cell carcinoma

Contact Info

Product

Resources

About